10-K: Xeris Biopharma Reports 2024 Results, Highlights Growth in Key Products

Xeris Biopharma's 2024 10-K filing reveals a company focused on commercial growth and strategic partnerships despite ongoing losses and competitive pressures.

Summary

• Xeris Biopharma, a commercial-stage biopharmaceutical company, reported its 10-K filing for the fiscal year ended December 31, 2024.
• The company focuses on therapies for chronic endocrine and neurological diseases, with key products including Recorlev, Gvoke, and Keveyis.
• Xeris leverages proprietary formulation technologies like XeriSol and XeriJect for new products and partnerships.
• The company incurred net losses of $54.8 million in 2024 and $62.3 million in 2023, with an accumulated deficit of $671.9 million as of December 31, 2024.
• Despite losses, Xeris saw a 28.2% increase in product revenue, reaching $196.6 million in 2024, driven by Gvoke and Recorlev.
• The company is developing XP-8121, a once-weekly subcutaneous injection of levothyroxine, and is planning a Phase 3 clinical trial.
• Xeris is pursuing formulation and development partnerships to enhance drug delivery using its XeriSol and XeriJect technologies.
• The company contracts with third parties for manufacturing and supply, with no plans to build its own infrastructure.
• Xeris faces intense competition from major pharmaceutical companies and generic versions of its products.
• The company's commercial success depends on protecting its intellectual property and proprietary formulation science.
• Xeris is subject to extensive government regulations, including FDA requirements and healthcare fraud and abuse laws.
• The company's stock price has been and is likely to continue to be volatile, and investors may lose part or all of their investment.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there is revenue growth in some key products, the company continues to experience net losses and faces significant competition and regulatory hurdles. The need for potential capital raises adds further uncertainty.

Positives

• Significant revenue growth in Recorlev and Gvoke demonstrates increasing market penetration.
• Advancement of XP-8121 into Phase 3 clinical trials represents a potential new growth driver.
• Strong intellectual property portfolio provides a competitive advantage.
• Strategic partnerships leverage proprietary technologies and broaden revenue streams.
• Experienced technical team manages supply chain operations effectively.
• Commitment to diversity, equity, and inclusion fosters a positive work environment.

Negatives

• Continued net losses and accumulated deficit raise concerns about long-term profitability.
• Reliance on third-party suppliers creates vulnerability in the supply chain.
• Intense competition from major pharmaceutical companies and generic products.
• Keveyis revenue decline due to generic competition.
• Stock price volatility poses a risk to investors.
• Potential limitations on the use of net operating loss carryforwards.

Risks

• The company may require additional capital to sustain its business, potentially causing dilution to stockholders.
• Commercial success depends on market acceptance of products and product candidates.
• Reimbursement decisions by third-party payors may affect pricing and market access.
• Clinical trials may fail to demonstrate efficacy and safety.
• Products may have undesirable side effects, delaying or preventing marketing approval.
• The company's ability to protect its intellectual property is crucial.
• Healthcare reform and cost containment measures may limit profitability.
• The company is subject to healthcare fraud and abuse laws.
• Disruptions at the FDA and other government agencies could hinder regulatory processes.
• The company may lose the services of key members of senior management.
• The company's data collection and processing activities are governed by restrictive regulations governing the use, processing and, in certain jurisdictions, cross-border transfer of personal information.

Future Outlook

The company expects to continue incurring net losses as it commercializes its products, develops new therapies, and operates as a public company. They believe their cash resources are sufficient to sustain operations and capital expenditure requirements for at least the next twelve months.

Management Comments

• The company's strategy is to build a profitable biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases.
• Xeris is uniquely positioned to execute on this strategy through the continued growth of our three commercial products, which enables us to invest in and develop therapies for unmet medical needs.
• We believe this will generate a value to all of our stakeholders.

Industry Context

The biopharmaceutical industry is characterized by intense competition and a strong emphasis on proprietary products. Xeris faces potential competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies.

Comparison to Industry Standards

• Corcept Therapeutics markets Korlym (mifepristone) for endogenous Cushings syndrome.
• Recordati markets Signifor (pasireotide) and Isturisa (osilodrostat) for Cushing's disease.
• Amphastar markets Baqsimi, an intranasal glucagon dry powder, for severe hypoglycemia.
• Novo Nordisk commercializes Zealand Pharmas dasiglucagon auto-injector, Zegalogue, for severe hypoglycemia.
• Torrent Pharmaceuticals markets a generic version of Keveyis.
• Cycle Pharmaceuticals partnered with Torrent to launch Ormalvi, a branded generic version of Keveyis.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises.
• Employees may experience uncertainty due to ongoing losses and potential restructuring.
• Customers (patients) may benefit from new therapies and improved access to existing products.
• Suppliers and creditors face potential risks due to the company's financial condition.

Next Steps

• Continue commercialization efforts for Recorlev, Gvoke, and Keveyis.
• Advance XP-8121 into Phase 3 clinical trials.
• Pursue formulation and development partnerships.
• Manage supply chain operations effectively.
• Monitor and comply with evolving regulatory requirements.

Key Dates